Sign In
Buy PGEN
$6.27
+0.330 (+5.56%)
At Close: Jul 31, 2026
Precigen Reports First Quarter 2024 Financial Results and Business Updates
04:05pm, Tuesday, 14'th May 2024
– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presenta
GERMANTOWN, Md. , May 8, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of
GERMANTOWN, Md. , April 24, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives
Actym Therapeutics Appoints Thomas Smart as CEO
09:00am, Wednesday, 24'th Apr 2024
BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
04:05pm, Thursday, 28'th Mar 2024
– Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – RRP is a
Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript
08:49pm, Tuesday, 19'th Mar 2024
Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript
Precigen Reports Full Year 2023 Financial Results and Business Updates
04:05pm, Tuesday, 19'th Mar 2024
– Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an accelerated approval pathway in the seco
GERMANTOWN, Md. , March 12, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
04:05pm, Tuesday, 05'th Mar 2024
GERMANTOWN, Md. , March 5, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
04:05pm, Tuesday, 06'th Feb 2024
GERMANTOWN, Md. , Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of
Precigen: RRP Targeting With AdenoVerse Technology Platform
07:39pm, Friday, 19'th Jan 2024
FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA fi
– Designation is an important step toward bringing this potentially life-changing therapy to European patients – – EU Orphan Drug Designation is the first regulatory designation for a gorilla ad
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 08'th Jan 2024
– PRGN-2012 Phase 2 pivotal study data in RRP is anticipated in the second quarter of 2024; the Company plans to submit a BLA under an accelerated approval pathway in the second half of 2024; c
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 18'th Dec 2023
GERMANTOWN, Md., Dec. 18, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o
5 ‘Jackpot' Stocks to Buy for 2024 for 10X Gains
03:38pm, Monday, 04'th Dec 2023
Last week, I revealed five “jackpot” stocks to buy for 2024.
